Biomarkers & Advanced Technologies Core

To support the overarching goal of the ERC-CFAR to end the HIV epidemic, the Biomarker and Advanced Technology Core (BATC) will provide state-of-the-art and innovative technologies, services and consultations to accelerate the development of novel approaches for prevention and cure including vaginal rings for sustained ART release (prevention), broadly neutralizing antibodies (bNAb) (prevention and cure), potent immunoactivators such as IL-15 superagonists (prevention and cure), and vaccines (prevention). The BATC will also support implementation research to improve the effectiveness of pre-exposure prophylaxis (PrEP), PEP (post-exposure prophylaxis) and treatment as prevention (TasP). The BATC infrastructure was developed specifically in response to the identified and articulated needs of established HIV/AIDS researchers and new investigators who are expanding their research programs to include HIV/AIDS-related studies at Einstein, Rockefeller, and CUNY. The BATC is also highly responsive to providing technical support to enable investigators to accomplish the current and emerging goals of the two Scientific Working Groups (SWGs), the HIV Eradication SWG and the Patient and Population Health Outcomes Research (PPHOR) SWG.

  • To provide investigators with the infrastructure and optimized technologies and protocols to support their HIV prevention studies.
  • To provide investigators with technological support to investigate and evaluate novel approaches to achieve a functional cure for HIV.
  • To provide a centralized resource for supporting HIV pathogenesis studies.
  • To provide access to deep HIV sequencing and mutational analysis for drug-resistance, immune escape and co-receptor tropism in laboratory and clinical isolates through the Case Western CFAR (
  • To transfer new technologies from individual ERC-CFAR research labs or from labs at other institutions into the BATC to make them broadly available to ERC-CFAR members.
  • To train ERC-CFAR investigators in molecular and cellular techniques for HIV research.
  • For further information or to access the Biomarker and Advanced Technologies Core services, please contact Drs. Berman or Almo.